Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, debilitating complication of cancer therapy that is defined by axonal degeneration and sensory dysfunction. Although axonal loss is the defining pathology in CIPN, the cellular events that initiate the neuropathic cascade have been unclear. The study summarized here addresses the cellular origin of CIPN and potential upstream therapeutic targets.
Across two mechanistically distinct chemotherapeutic agents, paclitaxel and cisplatin, the investigators report that chemotherapy induces cellular senescence, but this effect is unexpectedly localized to peripheral fibroblasts rather than neurons. According to the source, neuronal cells did not become senescent in response to these chemotherapies, indicating a non-neuronal cellular source for the initiating signal in CIPN.
The authors demonstrate that senescent peripheral fibroblasts act upstream of neuronal injury and initiate CIPN. The finding reframes CIPN as a condition whose trigger is located in the peripheral stromal compartment rather than within sensory neurons themselves. The source reports that both genetic and pharmacologic elimination of senescent fibroblasts prevented the development of neuropathy and that removing these cells could reverse established disease.
In the mechanistic hierarchy presented, fibroblast senescence precedes and leads to activation of neuronal SARM1, a mediator known to drive axonal degeneration. The study places senescent fibroblasts upstream of SARM1 activation, linking a stromal senescence program to the neuronal degeneration that defines CIPN.
Senescent fibroblasts produce a senescence-associated secretory phenotype (SASP) that, according to the report, drives neuropathic injury. The SASP in this context is dependent on MK2 signaling. The source indicates that the deleterious effects of senescent fibroblasts on peripheral nerves are mediated through an MK2-dependent secretory program.
The authors tested both genetic and pharmacological strategies to remove senescent fibroblasts. In the experiments described, ablation of these cells prevented the onset of neuropathy following chemotherapy and was sufficient to reverse established neuropathic disease. These results support a causal role for senescent peripheral fibroblasts in both initiation and maintenance of CIPN, and they suggest that senolytic approaches may have therapeutic benefit.
Targeting the MK2 pathway—either genetically or pharmacologically—suppressed the SASP produced by senescent fibroblasts, preserved peripheral innervation, and restored sensory function in the reported studies. This positions MK2 inhibition as a potential therapeutic strategy to block the fibroblast-derived signals that lead to axonal degeneration in CIPN.
These findings redefine the cellular origin of CIPN, shifting focus from neuron-intrinsic injury to senescent peripheral fibroblasts and their MK2-dependent SASP. The results identify fibroblast senescence and MK2 signaling as candidate targets for preventing or treating chemotherapy-associated neuropathy. Because the source document is a preprint, these results have not been peer-reviewed. The source does not provide detailed experimental parameters, translational timelines, or clinical trial data; such details would need to be assessed in peer-reviewed publications and follow-up studies before clinical adoption.
The authors declare no competing interests in the source. Funders listed include NIH grants and Department of Defense support as reported in the preprint. The article is a preprint and has not undergone peer review; readers should interpret the findings in that context.
Overall, the report provides preclinical evidence that chemotherapy-induced senescence of peripheral fibroblasts, via an MK2-dependent SASP, initiates and sustains CIPN, and that genetic or pharmacologic removal of these senescent cells or inhibition of MK2 can prevent and reverse neuropathy.